ER-positive and HER2-negative metastatic or locally advanced breast cancer a germline or somatic brca mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status. This evidence concerns the gene ERBB2 and breast carcinoma.